Cannabinoids market seen reaching $120.57 billion by 2030

The cannabinoids market is projected to rise from $47.03 billion in 2025 to $56.75 billion in 2026, then more than double to $120.57 billion by 2030, according to The Business Research Company. Growth is being driven by broader medical cannabis legalization, rising chronic disease rates and expanding demand for pharmaceutical-grade cannabinoid products.

Why it matters: - The cannabinoids market is moving from a niche therapy segment into a larger pharmaceutical and consumer health category. - Faster growth could affect drug development, hospital distribution, regulated supply chains and investment in production capacity. - The forecast points to stronger demand for standardized cannabinoid products as medical use expands.

What happened: - The Business Research Company released its Cannabinoids Market Report 2026, covering market size, trends and global forecasts for 2026-2035. - The report estimates the global cannabinoids market will grow from $47.03 billion in 2025 to $56.75 billion in 2026. - The report projects the market will reach $120.57 billion by 2030, at a compound annual growth rate of 20.7%. - The report also includes a free sample and the full report.

The details: - Broader legalization of medical cannabis programs is one of the main growth drivers. - Rising cases of chronic pain and cancer are increasing demand for cannabinoid-based therapies. - Greater acceptance of alternative therapies is supporting market expansion. - Expansion of hospital pharmacy distribution networks is helping cannabinoid products reach more patients. - Development of standardized cannabinoid products is strengthening commercial adoption. - The forecast period is expected to be shaped by expanded clinical research into cannabinoids. - Rising demand for pharmaceutical-grade cannabinoid products is another key tailwind. - Clearer regulatory frameworks across global regions are expected to support market growth. - Growth in personalized cannabinoid-based medicines is also expected to add demand. - Increased investment in production infrastructure is likely to support supply. - The report expects stronger medical adoption of cannabinoid therapies. - CBD-focused products are gaining popularity. - Cannabinoids are being used more often to manage chronic illnesses. - Regulated cannabinoid supply chains are becoming more important. - Product purity and standardization are getting more attention.

Between the lines: - The report frames cannabinoids as compounds derived from marijuana that interact with the immune and central nervous systems. - The therapeutic case for cannabinoids is increasingly tied to chronic disease management and pharmaceutical research. - Chronic disease prevalence is a major demand signal, not just a market trend. - CDC data cited in the report showed about 194 million U.S. adults, or 76.4%, had at least one chronic condition in 2023. - The CDC breakdown showed 59.5% of young adults, 78.4% of midlife adults and 93% of older adults were affected. - The report cites systematic reviews of randomized controlled trials showing cannabinoid treatments can help with chronic noncancer pain. - North America held the largest share of the market in 2025 because of progressive legalization policies and established healthcare infrastructure. - Asia-Pacific is expected to be the fastest-growing region as regulatory clarity improves and clinical research expands. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

What's next: - The market’s next phase depends on how quickly clinical research, regulation and manufacturing capacity expand. - Greater use of pharmaceutical-grade products could push the category further into mainstream medical treatment. - Tighter regulation and higher purity standards may separate established suppliers from lower-quality competitors. - The Business Research Company says its 2026 reports also add market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards and market hotspot infographics. - The company listed Saumya Sahay as the contact for expert inquiries, along with regional phone numbers and marketing@tbrc.info.

The bottom line: - Cannabinoids are moving from a high-growth health category into a globally scaled market, with medical demand and regulatory clarity as the biggest catalysts.